<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861090</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-743-4006</org_study_id>
    <nct_id>NCT04861090</nct_id>
  </id_info>
  <brief_title>A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis</brief_title>
  <official_title>Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aims of this study are to learn how many people with HAE Type I or Type II are&#xD;
      attack-free when treated with lanadelumab in real life. This includes the number of people&#xD;
      that are attack-free when lanadelumab is given every 2 and every 4 weeks.&#xD;
&#xD;
      This study is about collecting existing data only; participants will not receive lanadelumab&#xD;
      as part of this study. No new information will be collected during this study. Only data&#xD;
      already available at the participant's doctor's office will be reviewed and collected for&#xD;
      this study.&#xD;
&#xD;
      Participants do not need to visit their doctor in addition to their normal visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Free of Hereditary Angioedema (HAE) Attacks Treated With Lanadelumab</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Percentage of participants who are free of HAE attacks will be reported. A HAE attack is defined as the symptoms or signs consistent with an attack in at least 1 of the following locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Free of HAE Attacks Treated With Lanadelumab Administered Every Two Weeks</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Percentage of participants who are free of HAE attacks treated with lanadelumab which was administered every two weeks will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Free of HAE Attacks Treated With Lanadelumab Administered Every Four Weeks</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Percentage of participants who are free of HAE attacks treated with lanadelumab which was administered every four weeks will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Specific HAE Attack Occurrence</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Percentage of participants with specific HAE attack occurrence (e.g. attacks of specific localization, attacks requiring on-demand medication, life-threatening attacks) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who are Free of HAE Attacks Relative to Prior Treatment</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Percentage of participants who are free of HAE attacks relative to prior treatment (e.g. prior prophylaxis treatment or on-demand medications) among participants treated with lanadelumab will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Characterized With Every Four Weeks Adjustment</measure>
    <time_frame>Every 4 weeks from start of treatment (Up to Month 12)</time_frame>
    <description>Number of participants will be characterized with every four weeks adjustment (e.g. weight, age, duration of disease, history of life-threating attacks, length of attack-free interval during lanadelumab treatment) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Characterized Based on Primary Reasons for Down Titration</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Number of participants will be characterized based on primary reasons for down titration will be reported.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Participants With Hereditary Angioedema</arm_group_label>
    <description>Participants with HAE type I or type II who had initiated long-term prophylaxis (LTP) treatment with lanadelumab which was administered every two weeks (Q2W) or every four weeks (Q4W) or every six weeks (Q6W) or every eight weeks (Q8W) in accordance to Summary of Product Characteristics (SmPC), during a routine clinical setting will be followed up to 38 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult or adolescent participants (aged greater than or equal to [&gt;=] 12 years) with HAE&#xD;
        type I or type II who initiated LTP treatment with lanadelumab within a routine clinical&#xD;
        setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is aged &gt;= 12 years at the time of the last documented HAE attack in the&#xD;
             eligibility period.&#xD;
&#xD;
          -  Participant has a physician-confirmed diagnosis (or confirmation in medical records)&#xD;
             of HAE type I or type II.&#xD;
&#xD;
          -  Participant had initiated LTP with lanadelumab during the eligibility period.&#xD;
&#xD;
          -  Participant provides informed consent or assent prior to the initiation of any study&#xD;
             procedures (where required by local regulations).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant was enrolled in a therapeutic investigational drug or device trial during&#xD;
             the observation period.&#xD;
&#xD;
          -  Participant without documented HAE attacks in the pre-index period and/or without&#xD;
             available participant diary or systematic documentation of HAE attacks in the medical&#xD;
             records during the post index period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LKH-Universitätsklinikum Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lukas Koch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Angela Öllinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien (Medical University of Vienna)</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tamar Kinaciyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bouillet Laurence</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Launay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Magali Aubineau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aurelie Du Thanh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu de Paris Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Fain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hopitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume Armengol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charitè Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Markus Magerl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emel Aygören-Pürsün</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bettina Wedi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isa der Technischen Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Felix Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hämophilie Zentrum Rhein Main GmbH</name>
      <address>
        <city>Mörfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Inmaculada Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Randolf Brehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jens Greve</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navy Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fotios Psarros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Evangelia Kompoti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens' Hospital of Athens 'P. and A. Kyriakou'</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emmanouil Manolis Manousakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>15125</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Matthaios Speletas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/608ac7aef89629001e47b4e8</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

